Proteasomal receptors that recognize ubiquitin chains attached to substrates are key mediators of selective protein degradation in eukaryotes. Here we report the identification of a new ubiquitin receptor, Rpn13/ARM1, a known component of the proteasome. Rpn13 binds ubiquitin through a conserved amino-terminal region termed the pleckstrin-like receptor for ubiquitin (Pru) domain, which binds K48-linked diubiquitin with an affinity of approximately 90 nM. Like proteasomal ubiquitin receptor Rpn10/S5a, Rpn13 also binds ubiquitin-like (UBL) domains of UBL-ubiquitin-associated (UBA) proteins. In yeast, a synthetic phenotype results when specific mutations of the ubiquitin binding sites of Rpn10 and Rpn13 are combined, indicating functional linkage between these ubiquitin receptors. Because Rpn13 is also the proteasomal receptor for Uch37, a deubiquitinating enzyme, our findings suggest a coupling of chain recognition and disassembly at the proteasome.
In eukaryotes, selective protein degradation is performed primarily by the ubiquitin-proteasome pathway. The 26S proteasome is a huge macromolecular machine that contains a proteolytically active 20S core particle capped at one or both ends by a 19S regulatory particle 1 . The regulatory particle recognizes ubiquitinated substrates, deconjugates ubiquitin chains and unfolds substrates before their translocation into the core particle. Proteasome subunit Rpn10/S5a was shown to bind ubiquitin chains through ubiquitin-interacting motifs (UIMs) 2 . Receptors were subsequently identified that are not integral proteasome subunits, but deliver ubiquitinated targets to the proteasome (for reviews, see refs 3 and 4). Canonical members of this UBL/ UBA family of receptors are Rad23 (hHR23a/b in humans), Dsk2 (hPLIC-1/2 in humans) and Ddi1 (refs 5-9) . UBA domains of this protein family bind ubiquitin [10] [11] [12] , whereas their UBL domains interact reversibly with the proteasome, principally through Rpn1, but potentially also through Rpn10 (refs 13-15) .
Another interesting component of the proteasome is Rpn13/ ADRM1/ARM1 (refs [16] [17] [18] [19] [20] [21] , which docks at the regulatory particle through an N-terminal region that binds Rpn2 (refs 18, 21-23) . Its carboxy-terminal region binds deubiquitinating enzyme Uch37/ UCHL5 and enhances its isopeptidase activity 18, 20, 21 . Uch37 may function as an editing isopeptidase that rescues poorly ubiquitinated substrates from being degraded 24 .
A ubiquitin-interactor screen identifies Rpn13 Using a yeast two-hybrid screen, with a bait of ubiquitin lacking the last two glycines to prevent its conjugation 25 , we identified the N-terminal segment of human Rpn13 (hRpn13) as a ubiquitinbinding partner. The interaction was confirmed using murine Rpn13 (mRpn13) as bait against monoubiquitin and Rpn2 as prey (Fig. 1a) . Rpn13 from Saccharomyces cerevisiae (scRpn13) aligns with the ubiquitin-binding N-terminal region of hRpn13 (Fig. 1b) . Comprehensive sequence analysis using profiles and hidden Markov models failed to reveal similarity to known ubiquitin-or proteasome-binding motifs ( Fig. 1c and data not shown). Deletion mutants encompassing residues 1-150 were tested for tetraubiquitin binding, thus mapping the minimal binding domain to residues 1-130 (Fig. 1d) . Although smaller fragments of mRpn13 also showed detectable binding to ubiquitin, they were unstable and expressed poorly as glutathione S-transferase (GST) fusions.
The significance of the ubiquitin-Rpn13 interaction would be supported if it were conserved from yeast to mammals, particularly as budding yeast Rpn13 is truncated and the conserved N-terminal region (Fig. 1c) is only 25% identical to mammalian forms (Fig. 1b) . The existence of an unidentified ubiquitin receptor in yeast had been evident to us from the viability of an rpn10-uim rad23D dsk2D ddi1D mutant (data not shown). rpn13D mutants, which are viable but show defects in protein degradation 16, 26 , were used to test whether Rpn13 binds ubiquitin chains in the context of intact, purified proteasomes.
Rpn13 docks ubiquitin conjugates at the proteasome Ubiquitin chain binding by purified proteasomes can be assayed by native gel electrophoresis 5, 14 . Proteasomes are visualized in this system by an activity stain, using a fluorogenic peptide substrate. For wild type, the predominant proteasome species contains one regulatory particle on either end of the core particle cylinder (RP 2 CP). Ubiquitin chains, produced by the E2 enzyme Cdc34, bind to the proteasomes and confer reduced mobility (Fig. 2a) . This shift is not dependent on UBL/UBA proteins, because the proteasomes were prepared from rad23D dsk2D ddi1D mutants. A block substitution within the UIM in Rpn10 results in attenuation of the shift, reflecting Rpn10's known ubiquitin receptor function ( Fig. 2a ; refs 5 and 6). However, the existence of marked residual electrophoretic retardation by added chains (lane 4) indicates the presence of at least one additional ubiquitin receptor in purified proteasomes.
Addition of conjugates to proteasomes lacking Rpn13 resulted in an electrophoretic shift comparable to that of rpn10-uim samples (Fig. 2a) . Thus the yeast orthologue of mRpn13 is active in ubiquitin chain binding and can bind ubiquitin in the context of intact proteasomes. Indeed, its capacity for chain binding in this assay compares well with that of Rpn10. Remarkably, we observed an ostensibly complete abrogation of chain-dependent electrophoretic retardation when rpn10-uim rpn13D proteasomes were used (Fig. 2a) , suggesting that Rpn10 and Rpn13 are the two major ubiquitin receptors in the yeast proteasome. However, by varying the conditions of this assay, we could, as shown below, detect residual ubiquitin chain binding with rpn10-uim rpn13D proteasomes, consistent with the existence of a still-unidentified proteasomal ubiquitin receptor. The greater abundance of the RP 1 CP and core particle bands in rpn13D samples suggests that Rpn13 contributes to the stability of the regulatory particle-core particle interaction in vitro 26 . To determine whether rpn13D proteasomes were properly assembled, they were analysed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (Fig. 2b) . Apart from the absence of Rpn13 itself, the mutant proteasomes appeared to be wild type in composition. When recombinant Rpn13 was reconstituted onto mutant proteasomes after purification, their chain-binding defect was corrected (Fig. 2c) . Thus, the chain-binding assay appears to report on a specific Rpn13-ubiquitin chain interaction, and not a gross structural defect of rpn13D proteasomes. GST pull-down assays also indicated direct interaction of scRpn13 with ubiquitin (data not shown). In summary, these data indicate that Rpn13 is a novel proteasomal ubiquitin receptor.
Loops of yeast Rpn13 bind ubiquitin
To create mutants of scRpn13 deficient in ubiquitin binding and to study the functional significance of the interaction in vivo subsequently, we initially used NMR to solve the structure of full-length scRpn13. These studies revealed that Thr6-Leu101 forms two contiguous, antiparallel b-sheets with a configuration similar to the pleckstrin-homology structural domain (Fig. 3a) . In particular, a b-sheet comprising four antiparallel b-strands formed by I8-R11, E32-P37, W46-W50, and I64-L66 packs against a three-stranded sheet formed by M74-V76, I86-V90, and R96-W100. Juxtaposed to the three-stranded sheet are two b-strands formed by C15-N18 and L23-P26. The configuration of the b-strands centres around interactions between conserved aromatics within the protein core, including F10, F48, W50, W75, F87, F91, F98, F99 and W100. These findings are consistent with the crystal structure 27 would be a-helical, consistent with secondary structure predictions for K119-G127. Residues S106-G127 are absent, however, from all acquired spectra, suggesting that this region undergoes conformational exchange and does not form a rigid helix. In the accompanying manuscript 27 , we find that the cognate residues in mRpn13 and hRpn13 do form helices. K117-N130 of scRpn13 shares 35.7% sequence identity with mRpn13, but the presence of a glycine at position 127 likely destabilizes the helix, as might substitution of the sequence QDE at the beginning of the helix with the more basic sequence KDK in scRpn13. Also, a salt bridge 27 between E119 and R122 of mammalian Rpn13 is lost, as R122 is substituted with N123 in scRpn13.
To determine how scRpn13 binds ubiquitin, we performed an NMR titration series ( Supplementary Fig. 1 ), which implicated E41, E42, G44, F45, L66, E72, F91, S93 and R96 as being at the ubiquitin contact surface (Fig. 3b) . Interestingly, these residues are in the S2-S3, S4-S5 and S6-S7 loops (Fig. 3c) . The S4-S5 loop is strongly conserved in higher eukaryotes, as is F91, which is in the S6-S7 loop (Figs 1c and 3a) . scRpn13 binding to monoubiquitin is in 'fast exchange' by NMR, which is ideal for determining binding affinity by this method, and the affinity of scRpn13 for monoubiquitin was determined to be 65 mM (Fig. 3d ).
Rpn13 binds K48-linked diubiquitin with high affinity
We used NMR titration experiments to determine the stoichiometry of hRpn13 for monoubiquitin, K48-linked diubiquitin and tetraubiquitin (see Supplementary Information). Monoubiquitin and diubiquitin bound to Rpn13 with 1:1 stoichiometry, whereas two Rpn13 molecules bound one tetraubiquitin (Fig. 4a, b) . Therefore, although three potential diubiquitin elements exist within tetraubiquitin, no more than two Rpn13 molecules can be accommodated simultaneously. The exclusion of a third Rpn13 molecule is consistent with model structures of Rpn13-tetraubiquitin, in which steric clashes arise when three hRpn13 molecules bind neighbouring K48-linked ubiquitin subunits ( Supplementary Fig. 2 ). That Rpn13 binds diubiquitin elements of K48-linked chains is further validated in the accompanying manuscript 27 . In contrast to scRpn13, resonances broaden and shift as hRpn13 Pru binds monoubiquitin ( Supplementary Fig. 3 ). This behaviour is associated with stronger K d values, but prohibits their accurate calculation by the method used to determine the scRpn13-ubiquitin affinity. Fluorescence spectrophotometry was therefore used to spanning residues T6-L101, in which b-strands are indicated in blue and hydrophobic side chains in yellow. b, NMR titration experiments reveal scRpn13 residues that contact ubiquitin. The data were prepared as described in Methods and plotted. c, ScRpn13 residues that bind ubiquitin are within the S2-S3, S4-S5 and S6-S7 loops. Residues significantly affected by ubiquitin addition are displayed and labelled in red with their secondary structures in blue. d, scRpn13-KKD affinity for monoubiquitin is significantly reduced compared with wild type. Normalized chemical-shift perturbation values are plotted against molar ratios of monoubiquitin to wild-type scRpn13 (WT, red, green) or monoubiquitin to scRpn13-KKD (KKD, blue, purple). Each data line represents a specific amino acid, namely F45 (red and blue) and E72 (green and purple). Using Matlab version 7.2, the data were fitted to determine a binding constant of 65 mM for wild-type scRpn13 and an eightfold reduction in the affinity of scRpn13-KKD for monoubiquitin. determine hRpn13's affinity for monoubiquitin and diubiquitin, as hRpn13 (residues 1-150) contains two tryptophan residues and ubiquitin none. hRpn13 showed a surprisingly high affinity, with a K d value for monoubiquitin of about 300 nM (Fig. 4c, d ) and for diubiquitin of about 90 nM (Fig. 4c, d ). The value for diubiquitin binding is about 15-fold lower than that of hHR23a for tetraubiquitin 28 . The higher affinity of hRpn13 for ubiquitin, compared with scRpn13, reflects amino-acid substitutions at the contact surface. For example, in the accompanying paper 27 , residues F76 and D78 of hRpn13 were implicated in hRpn13 binding to monoubiquitin. In scRpn13, however, these residues are substituted with isoleucine and glycine, respectively.
Rpn13 recognizes a subset of ubiquitin-like proteins
We next analysed whether Rpn13 exhibits specificity for ubiquitin or broadly recognizes ubiquitin family members. Using GST pull-down assays, we confirmed that ubiquitin binds to full-length mRpn13 and that this interaction requires ubiquitin's hydrophobic patch, consisting of L8, I44 and V70 (Fig. 4e) . mRpn13 bound more potently to linear tetraubiquitin expressed as a GST fusion (GST 43Ub) or to purified K48-linked chains than to monoubiquitin (Fig. 4e and data not shown). Under the same experimental conditions, no binding was observed between the mRpn13 Pru domain and SUMO, Nedd8, ISG15 or FAT10 (Fig. 4f) . By contrast, mRpn13 appeared to bind to the UBL domains of multiple UBL/UBA proteins ( Supplementary  Figs 4 and 5) . We verified that hRpn13 Pru binds directly to the hHR23a and hPLIC2 UBL domains by NMR (Fig. 4g) , and determined a K d value of 36 mM for the hRpn13 Pru-hHR23a UBL domain complex (Fig. 4d and Supplementary Fig. 5 ). Overlapping residues in hRpn13 were affected by the addition of these UBL domains (Fig. 4g ) or ubiquitin 27 , suggesting that these interactions may be mutually exclusive.
Rpn13 mutant defective in ubiquitin recognition
Experiments described above implicated residues in Rpn13's S2-S3, S4-S5 and S6-S7 loops in binding ubiquitin (Fig. 3) . After introducing non-conservative substitutions for these residues individually or in combination, the resulting proteins were expressed in Escherichia coli, purified and characterized. We sought mutants that were defective in ubiquitin chain binding while being properly folded and proficient in proteasome binding. Separation of these functions is critical, as exemplified by previous studies of proteasomal ubiquitin receptor Rpn10. The rpn10D phenotype does not accurately reflect its function in ubiquitin recognition, because Rpn10 plays additional roles in the proteasome 6, 29 . The proteasome is destabilized in the absence of Rpn10 (ref. 29) , as is also observed in rpn13D mutants, at least under certain in vitro conditions ( Fig. 2; ref. 26 ). For Rpn13, unlike Rpn10, proteasome and ubiquitin binding are conferred by the same structural domain, and thus can be effectively separated only by precisely targeted mutations. Moreover, ubiquitin contact residues in Rpn13 are distributed over three distinct loops, and thus differ from those of Rpn10 by being non-contiguous and so not subject to simple block mutagenesis.
We assayed Rpn13-proteasome binding by adding GST-Rpn13 to purified proteasomes. Because of the GST moiety, the fusion protein Table of hRpn13 Pru binding affinities for K48-linked diubiquitin, monoubiquitin and the UBL domain of hHR23a. Values for ubiquitin binding were determined by using the fluorescence data of (c). NMR titration curves were used to determine the value for the UBL domain of hHR23a. e, mRpn13 Pru binds to the hydrophobic patch of ubiquitin containing I44. mRpn13 Pru domain was used in GST pull-down assays to assess binding to GST-tagged monoubiquitin and its mutant derivatives (I44A and triple mutant (3M*) L8-I44-V70). f, mRpn13 Pru domain was used in GST pull-down assays (as in (e)) to assess its binding to GST-fused ubiquitin-like protein modifiers. g, Rpn13 binds to the hPLIC2 and hHR23A UBL domains. 1 H, 15 N heteronuclear single-quantum coherence spectra of 15 N-labelled hRpn13 Pru alone (black) and with twofold molar excess hPLIC2 (red) or hHR23A (blue) UBL domain indicates their direct interaction. Although the effect is greater for hPLIC2, these two UBL domains affect common residues in hRpn13 Pru, suggesting that they bind the same surface.
results in strong electrophoretic retardation in native gels; this effect is seen with rpn13D but not wild-type proteasomes (Fig. 5a) . Thus Rpn13 assembled into the proteasome was not exchangeable with added GST-Rpn13, indicating that scRpn13 is a true proteasome subunit. Two putative ubiquitin contact-site mutants of Rpn13 were shown to be proficient in proteasome assembly (Fig. 5b) . Several other mutants failed to pass this and other preliminary assays, typically because of global folding defects (data not shown). E41 and E42 are in the S2-S3 loop, and S93 in the S6-S7 loop (Fig. 5c ). These sites, though greater than 22 Å apart, are both situated proximally to bound ubiquitin in a model based on the mRpn13-monoubiquitin structure 27 (Fig. 5c ). To assay mutational effects on ubiquitin chain binding, we used the native gel-based assay introduced in Fig. 2a . Note that the mobility shift resulting from addition of GST-Rpn13 to the proteasome (Fig. 5a, b) is irrelevant to the chain-binding assay, because Rpn13 itself does not affect proteasome migration in gels. Only the larger GST-tagged form of Rpn13 can do so, and, in the ubiquitin chain-binding assay, untagged Rpn13 was used. Neither the S93D mutant nor the E41K, E42K mutant conferred a strong defect in the a, Reconstitution of proteasomes with recombinant GST-Rpn13. Proteasomes were purified from strains containing or lacking Rpn13 (SY775 and SY723). GST-Rpn13 (40 pmol) or buffer was mixed with proteasomes (5 pmol), which were resolved on native PAGE and visualized using suc-LLVY-AMC. The mobility shift caused by GST-Rpn13 is an indicator of its assembly into proteasomes. The presence of GST on Rpn13 is required to cause a mobility shift. All proteasomes used in this figure are from an rpn10-uim ubp6D genetic background. b, Mutations in Rpn13 do not attenuate assembly of Rpn13 into the proteasome. Reconstitution assays were performed as in a, but using a fourfold molar excess of GST-Rpn13. c, Structural model with mutations. Mutated residues (see d-f) were mapped onto a model structure of scRpn13 (dark grey) complexed with monoubiquitin (light grey). E41, E42 and S93 are displayed in red, ubiquitin-binding loops in blue. These residues map to the S2-S3 (E41K, E42K) and S6-S7 (S93D) loops. ARTICLES proteasome-ubiquitin interaction, although both conferred reduced mobility shifts compared with wild-type Rpn13 (Fig. 5d) . To impair ubiquitin binding further, we combined the S2-S3 and S6-S7 mutations. The resulting protein, a E41K, E42K, S93D triple mutant, referred to as scRpn13-KKD, was comparable to a buffer control in its influence on the proteasome's electrophoretic mobility in the presence of ubiquitin conjugates (Fig. 5e) . NMR titrations revealed that scRpn13-KKD binds monoubiquitin approximately eightfold more weakly than wild type ( Fig. 3d ; see also Supplementary Information). To ensure that these mutations did not affect Rpn13 structural integrity, we compared a 1 H, 15 N heteronuclear singlequantum coherence spectrum recorded on 15 N-labelled scRpn13-KKD with that of wild type (Fig. 5f ). Only resonances corresponding to the mutated residues or their immediate neighbours were shifted, indicating that these surface mutations did not affect Rpn13's structure. In addition, we identified the hRpn13 surface that binds Rpn2, which is remote from the substituted residues 27 . The corresponding surface in scRpn13 is preserved in Rpn13-KKD as none of the residues within it were affected. Thus, Rpn13-KKD appeared to be suitable for in vivo analysis of the physiological function of ubiquitin recognition by Rpn13.
Phenotype of the Rpn13-ubiquitin binding-site mutant
To test the biological significance of the Rpn13-ubiquitin interaction, we integrated the triple mutant allele into yeast in place of the wild-type chromosomal sequence. Functional defects in proteasomes can be revealed by plate assays such as sensitivity to the arginine analogue canavanine, whose incorporation into proteins causes misfolding and accelerated degradation. The enhanced substrate load
of canavanine when in the genetic background of an rpn10-uim mutation (Fig. 6a) . Thus, the rpn13-KKD mutation leads to a defect in proteasome function, and interacts synthetically with another specifically targeted proteasomal ubiquitin receptor mutation. Because Rpn13 can bind UBL/UBA proteins (Fig. 4g) , we also investigated its genetic relationship with Dsk2 and Rad23. rpn13-KKD also showed a strong synthetic interaction with a null allele of proteasomal ubiquitin receptor Dsk2 (Fig. 6a) . In the case of Rad23, the genetic interaction was comparatively modest. These data support the view that the docking of ubiquitin conjugates at the proteasome by UBL/ UBA proteins is not mediated obligatorily by Rpn13. In addition, binding assays performed with purified proteasomes and the UBL domains of Rad23 and Dsk2 indicate that Rpn13 is not the sole receptor for UBL/UBA proteins on the proteasome (Supplementary Fig. 7) . The results of the binding assays are consistent with our previous report that proteasome subunit Rpn1 binds UBL/ UBA proteins 14 . Further work is required to define more precisely the extent to which Rpn13-dependent docking of ubiquitin conjugates at the proteasome is mediated or regulated by UBL/UBA proteins.
To test whether amino-acid substitutions in the ubiquitin-binding loops of Rpn13 can lead to global defects in ubiquitin metabolism, whole-cell extracts from our mutants were examined by immunoblotting. High molecular mass ubiquitin conjugates, which are enriched in proteasome substrates, accumulated in the rpn13-KKD rpn10-uim double mutant (Fig. 6b) . The defect is synthetic, as with the canavanine sensitivity of the double mutant (Fig. 6a) . We also observed an in vivo proteolytic defect in the rpn13-KKD mutant (Fig. 6c ), using the model proteasome substrate Ub Rpn13. a, Canavanine sensitivity of single and double mutants in ubiquitin receptor genes. Cells in late log phase (top: SY998b, SY980f, SY1004c and SY920b; middle: SY1076, SY1073a, SY1012a and SY1080a; bottom: SY1076, SY1074a, SY1012a and SY1082a) were serially diluted and stamped on plates using a pin array. Plates were incubated at 30 uC for either 2 (left) or 3 (right) days. b, Endogenous ubiquitin conjugate levels in proteasomal ubiquitin receptor mutants. Cells (SY998a, SY980a, SY1004a and SY920a) were grown to log phase, and whole-cell extracts prepared. Proteins were resolved by 4-12% gradient SDS-PAGE, transferred to polyvinylidene fluoride, and probed with antibody against ubiquitin. The membrane was stripped and probed with antibody against eIF5a. c, Substrate stabilization in rpn13-KKD mutants. Cells (SY992b, SY1004b) expressing Ub V76 -Val-e DK -b-gal from a GAL promoter were grown to mid-log phase under inducing conditions. Protein synthesis was quenched at time zero by adding cycloheximide. Aliquots were withdrawn at the time points indicated, and lysates prepared. Proteins were visualized by SDS-PAGE/immunoblot analysis, using an antibody to b-galactosidase, and quantified with imaging software (Kodak EDAS 290). The rate of degradation of Ub V76 -Val-e DK -b-gal was reduced approximately twofold in the rpn13-KKD mutant compared with wild type. Asterisks indicate distinct b-galactosidase-derived partial breakdown products, whose relative intensities differ between wild type and mutant. d, rpn13-KKD mutants are not deficient in proteasome levels. Cells (SY992a, SY1004a) were grown and lysed as in e. Extract (150 mg) was resolved by native PAGE, and proteasome complexes visualized using suc-LLVY-AMC (top) and Coomassie blue as a loading control (middle). The asterisk indicates the expected position of the proteasome core particle, which is not visualized owing to low levels. Extracts were also subject to a quantitative proteasome assay, using suc-LLVY-AMC (bottom). e, Proteasomes from rpn13-KKD mutants are loaded with Rpn13-KKD protein. Cells (SY933, SY936, SY950 and SY952) were grown to late log phase at 30 uC in yeast extract (10 g l Defects in proteasome assembly have been observed in rpn13D proteasomes ( Fig. 2; ref. 26) , and could potentially account for the phenotypes observed in Fig. 6a-c . We therefore analysed the assembly state of rpn13-KKD proteasomes by running native gels on freshly prepared, unfractionated cell extracts 31 . We observed no significant change in level, assembly or peptidase activity in rpn13-KKD proteasomes (Fig. 6d) . Surprisingly, no assembly defect was observed for rpn13D proteasomes (Fig. 6e) . Thus, assembly defects previously observed for rpn13D proteasomes are apparently a result of in vitro handling.
Although the recombinant Rpn13-KKD protein is properly folded and assembled onto purified proteasomes in vitro, it remained possible that the mutant protein would be absent from proteasomes in vivo as a result of its being rapidly degraded. To assess the extent of Rpn13-KKD loading of endogenous proteasomes, we used the GST-Rpn13 add-back assay of Fig. 5a , where purified proteasomes were used. In unfractionated cell extracts, GST-Rpn13 similarly shifted rpn13D proteasomes (Fig. 6e) . rpn13-KKD proteasomes behaved as wild type in this assay, indicating that they were fully loaded with Rpn13-KKD. We conclude that the phenotypes of the rpn13-KKD mutant do not reflect deficient proteasome assembly or deficient loading of Rpn13 onto proteasomes, but are specifically related to its impaired ubiquitin-binding site.
Discussion
We report here the identification of a new ubiquitin receptor for the proteasome, Rpn13, which is unrelated to Rpn10 and the three UBL/ UBA proteins. Moreover, Rpn13 defines a new class of ubiquitin recognition surfaces, differing dramatically from other proteasomal ubiquitin receptors. First, whereas the UBL/UBA proteins (and perhaps Rpn10) have distinct ubiquitin-and proteasome-binding domains that are separated by flexible linkers, Rpn13 is docked into the proteasome through a surface that is in close spatial proximity to its ubiquitin-binding region. Thus Rpn13 may provide for a ubiquitin chain with precise positioning and polarity. Second, the UBL/ UBA proteins, having a large population free of the proteasome and often multiple ubiquitin-binding domains, are better equipped than Rpn13 to capture ubiquitinated substrates and then deliver them to the proteasome. Third, UBL/UBA proteins are also capable of protecting the chain during transit to the proteasome, as they inhibit deubiquitination 6, 32, 33 . In striking contrast, Rpn13 promotes chain deubiquitination 18, 20, 21 . Binding to Rpn13 both facilitates the deubiquitinating activity of Uch37 (refs 20 and 21) and links Uch37 to the proteasome, suggesting that Rpn13 plays a major role in ubiquitin chain disassembly at the proteasome. Third, Rpn13 is exceptionally proficient at binding monoubiquitin and diubiquitin compared with other ubiquitin receptors associated with proteasome-mediated degradation. Although it is widely supposed that extended ubiquitin chains are required for degradation, contrary observations have been reported, in which monoubiquitin targets proteins to the proteasome 24, 34, 35 . Such substrates, although possibly rare, may be more strongly dependent on Rpn13 than those marked by chains.
Rpn13 resembles Rpn10 in its ability to bind ubiquitin-like domains of the UBL/UBA ubiquitin receptors (Fig. 4d, g and Supplementary Figs 4 and 5) , implying that Rpn13 may recruit substrates to the proteasome directly or indirectly through UBL/UBA proteins. These observations support a hypothetical model whereby conjugates bind UBL/UBA family members, which dock them to the proteasome and pass them to the intrinsic receptors Rpn10 and Rpn13. In addition, compound complexes may be formed, in which a single conjugate is simultaneously bound by an intrinsic ubiquitin receptor and a UBL/UBA protein. Compound complexes may be favoured when longer chains are delivered, leading to more stable chain-proteasome interactions, and thus more rapid substrate degradation.
Ubiquitin and the proteasome are both essential, but remarkably the inactivation of all five known proteasomal ubiquitin receptors in the same yeast strain does not appear to be lethal (data not shown). In our assays, the residual chain-binding capacity of rpn10-uim rpn13-KKD rad23D dsk2D ddi1D proteasomes is modest (Fig. 5e) , suggesting that the highest-affinity intrinsic receptors are now known. The unidentified receptor may be of lower affinity but comparable functionality, or it may be a receptor of typical affinity that is not intrinsic to the proteasome, such as Rad23/hHR23.
The phenotypic properties of multiply receptor-deficient strains suggest functional redundancy ( Fig. 6; refs 5 and 32 ). This may reflect robustness in their principal function of delivering substrate to the proteasome. Given the number of known receptors, it is likely that docking of the chain at any of multiple locations in the proteasome will support breakdown of the target protein. However, there is apparently a deeper and more interesting functional relationship among ubiquitin receptors as well, in which they play distinct roles. For example, they have various phenotypes in isolation, albeit not lethal ones. Furthermore, proteasome function appears substantially compromised in multiple receptor-deficient strains (refs 5 and 32, and S.E. and D.F., unpublished observations). When different receptor mutants are compared, the relative strengths of the degradation defects vary from substrate to substrate 6 . Thus, the receptors show in vivo specificity, although it remains unclear how specific they are and what the mechanistic basis of this specificity is. Finally, functionally redundant behaviour as inferred from mutant phenotypes may not reflect the functioning of the wild-type system in a straightforward manner, because compensation can mask differentiated activities. With more detailed characterization, the individuality of proteasomal ubiquitin receptors and its mechanistic basis should become clearer.
METHODS SUMMARY
Yeast genetics and two-hybrid screen. Standard methods were used for yeast genetics, growth assays and protein turnover assays (see Supplementary  Information) . A complete list of yeast strains is given in the Supplementary Information. Sequences corresponding to mouse ubiquitin lacking two terminal glycines (UbDGG) were subcloned into pYTH9 vector 36 , creating fusion proteins with the Gal4 DNA-binding domain (bait). Yeast strain Y190 was transformed with bait vector, and human fetal brain complementary DNA (cDNA) library (Clontech) was screened as previously described 36 . Antibodies and plasmids. Antibodies used were: anti-myc (9E10) and anti-Ub (P4D1) from Santa Cruz Biotechnology; anti-ADRM1 (anti-Rpn13) from Biomol; and anti-b-galactosidase (Promega). All constructs used in this study are described in Supplementary Information. Protein purification and biochemical assays. Recombinant proteins were expressed in and purified from Rosetta cells (Novagen). Proteasome was affinity-purified essentially as described 37 . Immunoprecipitation, immunoblotting and GST pull-down assays were performed as previously described 25 . Native gel analysis was performed as in ref. 5 . More detailed descriptions are available in Supplementary Information. NMR spectroscopy. We determined the structure of full-length scRpn13 as described in Supplementary Information, with the data summarized in Supplementary Table 1 . The resulting structures are available through Protein Data Bank accession number 2Z4D. Binding surfaces and affinities were determined as described in Supplementary Information.
